atorvastatin has been researched along with verapamil in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 12 (48.00) | 29.6817 |
2010's | 11 (44.00) | 24.3611 |
2020's | 2 (8.00) | 2.80 |
Authors | Studies |
---|---|
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Barton, P; Ismair, M; Jupp, R; Riley, RJ; Soars, MG | 1 |
Bellman, K; Knegtel, RM; Settimo, L | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Boyd, RA; Randinitis, EJ; Reyner, EL; Stern, RH; Stewart, BH; Whitfield, L; Wu, X; Zegarac, EA | 1 |
Stewart, BH; Whitfield, LR; Wu, X | 1 |
Grand-Perret, T; Issandou, M | 1 |
Jacobson, TA | 1 |
Babita, K; Tiwary, AK | 1 |
Hatipoglu, SE; Iltimur, K; Tacar, O; Tuncer, CM | 1 |
Chang, KS; Choi, DH; Choi, JS; Han, HK; Hong, SP | 1 |
Choi, DH; Choi, JS; Shin, WG | 1 |
Srinivas, NR | 3 |
Rao, N | 1 |
Benet, LZ; Estudante, M; Maya, M; Morais, JG; Soveral, G | 1 |
Agarwal, M; Dash, RP; Ellendula, B; Nivsarkar, M | 1 |
Caran, T; Cibicek, N; Cibickova, L; Dobias, M; Ondra, P; Vorisek, V | 1 |
Liu, L; Liu, X; Tang, X; Wang, S; Xu, J; Yang, T; Zhang, J | 1 |
Hammer, HS; Khalaf, S; Kroetz, DL; Mortensen, C; Nielsen, F; Poetz, O; Rodriguez-Antona, C; Stage, TB; Steffensen, V; Svenningsen, ÅF; Xiong, C | 1 |
Abdulaziz, O; Ahmad, S; Ali, N; Ali, W; Aljuaid, A; Allahyani, M; Almehmadi, M; Alsaiari, AA; Ullah, A | 1 |
1 review(s) available for atorvastatin and verapamil
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 trial(s) available for atorvastatin and verapamil
Article | Year |
---|---|
Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion.
Topics: Adolescent; Adult; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Caco-2 Cells; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Female; Heptanoic Acids; Humans; Intestinal Mucosa; Male; Middle Aged; Pyrroles; Time Factors; Verapamil | 2000 |
Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Topics: Adolescent; Adult; Anticholesteremic Agents; Antiprotozoal Agents; Area Under Curve; Atorvastatin; Biomarkers; Calcium Channel Blockers; Clarithromycin; Creatine Kinase; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Itraconazole; Male; Mibefradil; Middle Aged; Pravastatin; Protein Synthesis Inhibitors; Pyrroles; Simvastatin; Verapamil | 2004 |
Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
Topics: Adult; Anticholesteremic Agents; Area Under Curve; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Calcium Channel Blockers; Cytochrome P-450 CYP3A; Drug Interactions; Heptanoic Acids; Humans; Male; Pyrroles; Verapamil | 2008 |
21 other study(ies) available for atorvastatin and verapamil
Article | Year |
---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
Topics: Cell Line; Drug Discovery; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters | 2012 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Atorvastatin transport in the Caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter.
Topics: Acetic Acid; Anion Transport Proteins; Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoic Acid; Biological Transport; Caco-2 Cells; Calcium Channel Blockers; Carbon Radioisotopes; Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone; Carboxylic Acids; Carrier Proteins; Cell Polarity; Cyclosporine; Drug Interactions; Heptanoic Acids; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indicators and Reagents; Ionophores; Niacin; Protons; Pyrroles; Verapamil; Vinblastine | 2000 |
Multidrug resistance P-glycoprotein is not involved in cholesterol esterification.
Topics: Acridines; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cholesterol; Cholesterol Esters; DNA-Binding Proteins; Fluoresceins; Fluorescent Dyes; Heptanoic Acids; Humans; Isoquinolines; Kinetics; Multidrug Resistance-Associated Proteins; MutS Homolog 3 Protein; Probenecid; Progesterone; Pyrroles; Sterol O-Acyltransferase; Tetrahydroisoquinolines; Tumor Cells, Cultured; Verapamil | 2000 |
Skin lipid synthesis inhibition: a possible means for enhancing percutaneous delivery of levodopa.
Topics: Administration, Cutaneous; Animals; Anticholesteremic Agents; Antiparkinson Agents; Atorvastatin; beta-Alanine; Calcium Channel Blockers; Calcium Chloride; Cholesterol; Dose-Response Relationship, Drug; Ethanol; Female; Heptanoic Acids; In Vitro Techniques; Levodopa; Male; Pyrroles; Rats; Rats, Wistar; Serine C-Palmitoyltransferase; Skin; Sphingosine; Time Factors; Verapamil | 2004 |
Single coronary artery with retroaortic course. An unusual origin of right Valsalva sinus.
Topics: Adult; Aspirin; Atorvastatin; Chest Pain; Coronary Vessel Anomalies; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Platelet Aggregation Inhibitors; Pyrroles; Radiography; Sinus of Valsalva; Vasodilator Agents; Verapamil | 2006 |
Effect of atorvastatin on the intravenous and oral pharmacokinetics of verapamil in rats.
Topics: Administration, Oral; Analysis of Variance; Animals; Area Under Curve; Atorvastatin; Calcium Channel Blockers; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Interactions; Half-Life; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Male; Metabolic Clearance Rate; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil | 2008 |
Dual drug interactions via P-glycoprotein (P-gp)/ cytochrome P450 (CYP3A4) interplay: recent case study of oral atorvastatin and verapamil.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Pyrroles; Verapamil | 2008 |
Drug-drug interaction studies in preclinical species: should metabolite(s) kinetics be studied?
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Cytochrome P-450 CYP3A; Drug Design; Drug Interactions; Heptanoic Acids; Kinetics; Pharmacology, Clinical; Pyrroles; Verapamil | 2009 |
Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Purines; Pyrroles; Rifampin; Verapamil | 2009 |
Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Organic Anion Transporters; Purines; Pyrroles; Research Design; Rifampin; Verapamil | 2011 |
Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Digoxin; Heptanoic Acids; Intestinal Absorption; Pyrroles; Rats; Rats, Sprague-Dawley; Verapamil | 2013 |
Increased intestinal P-glycoprotein expression and activity with progression of diabetes and its modulation by epigallocatechin-3-gallate: Evidence from pharmacokinetic studies.
Topics: Animals; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Catechin; Diabetes Mellitus, Experimental; Disease Progression; Ileum; Intestinal Absorption; Male; Rats; Sodium-Potassium-Exchanging ATPase; Verapamil | 2015 |
Multi-drug intoxication fatality involving atorvastatin: A case report.
Topics: Acute Kidney Injury; Aged; Alcoholics; Anthraquinones; Anti-Inflammatory Agents; Antihypertensive Agents; Atorvastatin; Drug Overdose; Female; Forensic Toxicology; Gastrointestinal Contents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Indoles; Piperazines; Rhabdomyolysis; Suicide; Vasodilator Agents; Verapamil | 2015 |
Predicted contributions of cytochrome P450s to drug metabolism in human liver microsomes using relative activity factor were dependent on probes.
Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Diclofenac; Humans; Kinetics; Microsomes, Liver; Midazolam; Protein Isoforms; Testosterone; Tolbutamide; Verapamil; Warfarin | 2019 |
P-Glycoprotein Inhibition Exacerbates Paclitaxel Neurotoxicity in Neurons and Patients With Cancer.
Topics: Antineoplastic Agents, Phytogenic; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Cyclosporins; Dose-Response Relationship, Drug; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neurons; Paclitaxel; Peripheral Nervous System Diseases; Retrospective Studies; Risk Assessment; Risk Factors; Simvastatin; Verapamil | 2020 |
Atorvastatin and Fluvastatin Potentiate Blood Pressure Lowering Effect of Amlodipine through Vasorelaxant Phenomenon.
Topics: Amlodipine; Animals; Atorvastatin; Blood Pressure; Calcium; Calcium Channel Blockers; Calcium Channels; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Potassium Chloride; Rabbits; Rats; Rats, Wistar; Vasodilator Agents; Verapamil | 2023 |